SUDS3

Sin3 histone deacetylase corepressor complex component SDS3 · Q9H7L9 · SUDS3 on Sugi Atlas →

0 patent compounds predicted against SUDS3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SUDS3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Vorinostat in Children PHASE1/PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Bipolar Disorder With Alcoholism in Han Chinese nanUNKNOWN
Better Delineation of YY1 Related Phenotype and Epigenetic Signatures. nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family. nanUNKNOWN
Circadian Rhythms and Sleep in Familial DSPS and ASPS nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
The Phenotyping and Genotyping of Taiwanese Patients With Obstructive Sleep Apnea nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SUDS3 binder may also engage these)

ProteinNameSimilarity
Q5RBB8 1.000 Q5RBB8 →
Q8BR65 1.000 Q8BR65 →
A6H6W9 1.000 A6H6W9 →
O14639 0.958 O14639 →
Q12800 0.954 Q12800 →
X2JAU8 0.952 X2JAU8 →
Q9ERA0 0.951 Q9ERA0 →
Q7T2U9 0.950 Q7T2U9 →
Q6NZH6 0.949 Q6NZH6 →
Q9TUZ0 0.949 Q9TUZ0 →
Q8R3S6 0.948 Q8R3S6 →
STAT5B Signal transducer and activator of transcription 5B 0.948 landscape →
F1LSG8 0.947 F1LSG8 →
Q9TUM3 0.947 Q9TUM3 →
EXOC1 Exocyst complex component 1 0.947 landscape →
Q7Z6J6 0.947 Q7Z6J6 →
Q8K4Q0 0.947 Q8K4Q0 →
Q8CI71 0.946 Q8CI71 →
Q9NPF5 0.946 Q9NPF5 →
Q4V860 0.945 Q4V860 →
RPTOR Regulatory-associated protein of mTOR 0.945 landscape →
Q9TUZ1 0.945 Q9TUZ1 →
Q96JG6 0.944 Q96JG6 →
Q9JI44 0.943 Q9JI44 →
Q9Y4J8 0.943 Q9Y4J8 →
Q6NRB5 0.943 Q6NRB5 →
Q8K4G5 0.943 Q8K4G5 →
Q95115 0.943 Q95115 →
STAT5A Signal transducer and activator of transcription 5A 0.942 landscape →
Q5ZKV9 0.942 Q5ZKV9 →